Oric Historical Balance Sheet

ORIC Stock

USD 6.35 0.50 8.55%

Trend analysis of Oric Pharmaceuticals balance sheet accounts such as Net Tangible Assets of 268.5 M provides information on Oric Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Oric Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Oric Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Oric Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oric Pharmaceuticals is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

About Oric Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Oric Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Oric Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Oric Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Oric currently owns. An asset can also be divided into two categories, current and non-current.

Oric Pharmaceuticals Balance Sheet Chart

At present, Oric Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 4.3 M, whereas Total Current Liabilities is forecasted to decline to about 13.1 M.

Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Oric Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oric Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Oric Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.At present, Oric Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 4.3 M, whereas Total Current Liabilities is forecasted to decline to about 13.1 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	15.4M	20.5M	24.8M	13.1M
Other Current Liabilities	11.4M	16.8M	23.3M	24.5M

Total Current Liabilities Other Current Liab

Oric Pharmaceuticals balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Other Current Liab		0.91	-0.88	0.85	-0.99	0.45	0.03	0.82	0.91	0.32	0.84	0.83	0.45	-0.21	0.25	0.5	0.63	0.83	0.91	-0.82	0.84	0.84	0.91	-0.76	0.83	0.85
Total Current Liabilities	0.91		-0.88	0.86	-0.93	0.57	0.15	0.87	0.99	0.43	0.88	0.87	0.52	-0.27	0.3	0.68	0.7	0.86	0.97	-0.81	0.95	0.91	0.99	-0.76	0.87	0.95
Other Liab	-0.88	-0.88		-0.91	0.85	-0.36	0.2	-0.96	-0.92	0.01	-0.96	-0.98	-0.38	0.44	-0.47	-0.65	-0.68	-0.95	-0.79	0.97	-0.92	-0.85	-0.88	0.95	-0.98	-0.77
Net Tangible Assets	0.85	0.86	-0.91		-0.84	0.61	0.13	0.96	0.9	0.1	0.98	0.94	0.35	-0.41	0.45	0.65	0.67	0.97	0.73	-0.82	0.95	0.91	0.84	-0.79	0.94	0.77
Retained Earnings	-0.99	-0.93	0.85	-0.84		-0.49	-0.13	-0.8	-0.93	-0.43	-0.82	-0.8	-0.5	0.14	-0.17	-0.52	-0.63	-0.8	-0.93	0.78	-0.86	-0.83	-0.93	0.72	-0.8	-0.9
Accounts Payable	0.45	0.57	-0.36	0.61	-0.49		0.65	0.46	0.5	0.45	0.53	0.44	0.04	-0.5	0.51	0.65	0.75	0.48	0.5	-0.25	0.61	0.77	0.57	-0.18	0.44	0.66
Other Assets	0.03	0.15	0.2	0.13	-0.13	0.65		-0.08	0.07	0.65	-0.02	-0.16	0.14	0.17	-0.17	0.19	0.16	-0.06	0.11	0.39	0.15	0.23	0.11	0.47	-0.16	0.31
Total Current Assets	0.82	0.87	-0.96	0.96	-0.8	0.46	-0.08		0.92	-0.01	0.99	0.99	0.31	-0.45	0.47	0.61	0.65	1.0	0.75	-0.91	0.95	0.87	0.84	-0.89	0.99	0.72
Common Stock	0.91	0.99	-0.92	0.9	-0.93	0.5	0.07	0.92		0.35	0.92	0.91	0.51	-0.23	0.27	0.62	0.66	0.91	0.93	-0.86	0.97	0.88	0.97	-0.82	0.91	0.91
Property Plant Equipment	0.32	0.43	0.01	0.1	-0.43	0.45	0.65	-0.01	0.35		0.02	-0.03	0.35	0.43	-0.41	0.13	0.24	0.0	0.53	0.08	0.26	0.24	0.43	0.16	-0.03	0.58
Total Assets	0.84	0.88	-0.96	0.98	-0.82	0.53	-0.02	0.99	0.92	0.02		0.99	0.35	-0.49	0.52	0.69	0.69	0.99	0.76	-0.91	0.96	0.91	0.86	-0.88	0.99	0.77
Total Stockholder Equity	0.83	0.87	-0.98	0.94	-0.8	0.44	-0.16	0.99	0.91	-0.03	0.99		0.34	-0.49	0.52	0.67	0.68	0.98	0.76	-0.96	0.94	0.88	0.86	-0.94	1.0	0.74
Property Plant And Equipment Net	0.45	0.52	-0.38	0.35	-0.5	0.04	0.14	0.31	0.51	0.35	0.35	0.34		0.29	-0.23	0.46	-0.05	0.3	0.48	-0.34	0.43	0.32	0.51	-0.3	0.34	0.54
Net Debt	-0.21	-0.27	0.44	-0.41	0.14	-0.5	0.17	-0.45	-0.23	0.43	-0.49	-0.49	0.29		-1.0	-0.61	-0.66	-0.44	-0.18	0.44	-0.36	-0.58	-0.31	0.46	-0.49	-0.22
Cash	0.25	0.3	-0.47	0.45	-0.17	0.51	-0.17	0.47	0.27	-0.41	0.52	0.52	-0.23	-1.0		0.65	0.68	0.47	0.21	-0.47	0.4	0.61	0.34	-0.49	0.52	0.26
Non Current Assets Total	0.5	0.68	-0.65	0.65	-0.52	0.65	0.19	0.61	0.62	0.13	0.69	0.67	0.46	-0.61	0.65		0.74	0.59	0.55	-0.58	0.72	0.79	0.72	-0.55	0.67	0.74
Non Currrent Assets Other	0.63	0.7	-0.68	0.67	-0.63	0.75	0.16	0.65	0.66	0.24	0.69	0.68	-0.05	-0.66	0.68	0.74		0.64	0.66	-0.62	0.72	0.83	0.76	-0.58	0.68	0.76
Cash And Short Term Investments	0.83	0.86	-0.95	0.97	-0.8	0.48	-0.06	1.0	0.91	0.0	0.99	0.98	0.3	-0.44	0.47	0.59	0.64		0.74	-0.9	0.95	0.87	0.83	-0.88	0.98	0.72
Common Stock Shares Outstanding	0.91	0.97	-0.79	0.73	-0.93	0.5	0.11	0.75	0.93	0.53	0.76	0.76	0.48	-0.18	0.21	0.55	0.66	0.74		-0.75	0.84	0.84	0.97	-0.69	0.76	0.93
Non Current Liabilities Total	-0.82	-0.81	0.97	-0.82	0.78	-0.25	0.39	-0.91	-0.86	0.08	-0.91	-0.96	-0.34	0.44	-0.47	-0.58	-0.62	-0.9	-0.75		-0.84	-0.76	-0.83	1.0	-0.96	-0.68
Capital Surpluse	0.84	0.95	-0.92	0.95	-0.86	0.61	0.15	0.95	0.97	0.26	0.96	0.94	0.43	-0.36	0.4	0.72	0.72	0.95	0.84	-0.84		0.93	0.93	-0.8	0.94	0.88
Other Current Assets	0.84	0.91	-0.85	0.91	-0.83	0.77	0.23	0.87	0.88	0.24	0.91	0.88	0.32	-0.58	0.61	0.79	0.83	0.87	0.84	-0.76	0.93		0.91	-0.71	0.88	0.88
Other Stockholder Equity	0.91	0.99	-0.88	0.84	-0.93	0.57	0.11	0.84	0.97	0.43	0.86	0.86	0.51	-0.31	0.34	0.72	0.76	0.83	0.97	-0.83	0.93	0.91		-0.78	0.86	0.97
Total Liab	-0.76	-0.76	0.95	-0.79	0.72	-0.18	0.47	-0.89	-0.82	0.16	-0.88	-0.94	-0.3	0.46	-0.49	-0.55	-0.58	-0.88	-0.69	1.0	-0.8	-0.71	-0.78		-0.94	-0.61
Net Invested Capital	0.83	0.87	-0.98	0.94	-0.8	0.44	-0.16	0.99	0.91	-0.03	0.99	1.0	0.34	-0.49	0.52	0.67	0.68	0.98	0.76	-0.96	0.94	0.88	0.86	-0.94		0.74
Property Plant And Equipment Gross	0.85	0.95	-0.77	0.77	-0.9	0.66	0.31	0.72	0.91	0.58	0.77	0.74	0.54	-0.22	0.26	0.74	0.76	0.72	0.93	-0.68	0.88	0.88	0.97	-0.61	0.74

Click cells to compare fundamentals

Oric Pharmaceuticals Account Relationship Matchups

Oric Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	8.2M	11.3M	11.4M	16.8M	23.3M	24.5M
Total Current Liabilities	9.0M	15.2M	15.4M	20.5M	24.8M	13.1M
Net Tangible Assets	(90.1M)	289.8M	273.0M	222.4M	255.7M	268.5M
Retained Earnings	(166.4M)	(245.1M)	(334.2M)	(434.9M)	(562.8M)	(534.6M)
Accounts Payable	757K	1.9M	1.3M	944K	1.5M	1.1M
Other Assets	0.0	319K	521K	517K	594.6K	433.8K
Total Current Assets	296.7M	240.5M	210.5M	212.6M	262.3M	190.1M
Property Plant Equipment	2.2M	2.0M	2.4M	3.3M	3.7M	2.8M
Total Assets	299.0M	298.6M	247.2M	252.0M	274.1M	237.6M
Total Stockholder Equity	289.8M	273.0M	222.4M	224.1M	243.1M	200.5M
Property Plant And Equipment Net	2.0M	2.4M	3.3M	12.0M	2.9M	4.3M
Net Debt	(78.4M)	(224.1M)	(64.2M)	(13.2M)	(59.4M)	(62.4M)
Cash	78.4M	226.0M	66.8M	23.4M	59.4M	67.0M
Non Current Assets Total	2.3M	58.1M	36.7M	39.4M	11.9M	11.3M
Non Currrent Assets Other	319K	12.3M	11.5M	552K	9.0M	5.7M
Cash And Short Term Investments	293.6M	237.0M	206.3M	208.2M	256.0M	209.4M
Common Stock Shares Outstanding	21.9M	38.0M	39.7M	51.5M	69.7M	42.4M
Liabilities And Stockholders Equity	299.0M	298.6M	247.2M	252.0M	274.1M	237.6M
Non Current Liabilities Total	219K	10.5M	9.4M	7.5M	6.2M	5.9M
Capital Surpluse	2.6M	456.2M	518.2M	557.9M	641.5M	338.0M
Other Current Assets	3.1M	7.1M	4.2M	4.4M	6.3M	4.2M
Other Stockholder Equity	157.2M	518.2M	557.9M	658.8M	805.5M	452.9M
Total Liab	9.2M	25.7M	24.8M	27.9M	31.0M	27.0M
Net Invested Capital	289.8M	273.0M	222.4M	224.1M	243.1M	200.5M
Property Plant And Equipment Gross	2.0M	7.4M	9.0M	9.4M	10.4M	6.7M
Accumulated Other Comprehensive Income	(31K)	(103K)	(1.3M)	258K	379K	398.0K
Net Working Capital	287.7M	225.4M	195.1M	192.1M	237.4M	198.5M
Short Term Debt	546K	1.9M	2.7M	2.8M	3.2M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:

How To Invest In Oric

Details

Is Oric Stock a good investment?

Details

What is Oric Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.83)

Return On Assets

(0.34)

Return On Equity

(0.55)

The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oric Historical Balance Sheet

About Oric Balance Sheet Analysis

Oric Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Oric Pharmaceuticals balance sheet Correlations

Oric Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oric Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 0.99	Total Current Liabilities
Other Stockholder Equity	+ 0.99	Total Current Liabilities
Total Assets	+ 0.99	Total Current Assets

Cash	- 1.0	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Net Invested Capital	- 0.98	Other Liab
Total Stockholder Equity	- 0.98	Other Liab
Net Invested Capital	- 0.96	Non Current Liabilities Total
Non Current Liabilities Total	- 0.96	Total Stockholder Equity